Puma Biotechnology

PBYI · NASDAQ

$10.76+$0.55 (+5.39%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.21

PBYI analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform0
Sell0

12-month price target · 3 analysts

Average $5.10 (−52.6% downside)

Low: $5.05
Now: $10.76
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

PBYI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
TD Cowen	Aug 7, 2026	Maintains	Hold	$5.00 → $6.00	27%

The case for and against

Updated Jun 12, 2025

Bull case

Puma Biotechnology Inc. demonstrated a positive performance in 4Q24, with net sales of NERLYNX exceeding previous guidance and showing a significant increase in the total number of bottles sold compared to both 4Q23 and 3Q24. The company reported a reduction in selling, general, and administrative (SG&A) expenses, which fell to $16.6 million from $20.2 million year-over-year, indicating enhanced cost management. Additionally, encouraging clinical data for alisertib and a strategic recommendation to expand patient enrollment in trials highlight the potential for future growth in both sales and clinical outcomes.

Bear case

Puma Biotechnology Inc. has revised its revenue projections for 2025 downward, estimating $216.4 million instead of the previously anticipated $232.7 million, alongside a decrease in non-GAAP diluted EPS forecast from $0.74 to $0.43. The company's fourth-quarter 2024 Nerlynx sales show minimal increase year-over-year at $54.4 million, but this figure reflects a decline from $56.1 million in the preceding quarter, signaling potential stagnation in sales momentum. Additionally, a 7% quarter-over-quarter drop in new prescriptions highlights challenges in maintaining and growing its customer base, casting further uncertainty on future revenue performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.